Alfredo Budillon

Chief Experimental Pharmacology Unit

Fondazione IRCCS Istituto Nazionale dei Tumori

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Alfredo Budillon is the Chief of the Experimental Pharmacology Unit at Istituto Nazionale Tumori IRCCS Fondazione Pascale in Italy. His research focuses on the intersection of cancer and environmental factors, with recent publications addressing topics such as biomarkers for treatment response, proteomic analysis in oncology, and the impacts of pollution on tumor development. He is also exploring epigenetic approaches to overcome therapeutic resistance and novel prognostic markers in cancer progression.

Articles (15)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (5)

Orlando Paciello

ITALY

View details

Maria Grazia Vitale

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

CANNELLA LUCIA

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

Salvatore Valiante

Associate professor

University of Naples Federico II

ITALY

View details

Alessandra Leone

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Alfredo Budillon

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

Testicular Tumors and Environmental Pollution: A Comparative Oncoepidemiology Study in the Campania Region from 2020 to 2023

Serum-Based Proteomic Approach to Identify Clinical Biomarkers of Radiation Exposure

Proteomic Analysis of Biomarkers Predicting Treatment Response in Patients with Head and Neck Cancers

Assessing Urinary Para-Hydroxyphenylacetic Acid as a Biomarker Candidate in Neuroendocrine Neoplasms

ICOSLG Is Associated with Anti-PD-1 and Concomitant Antihistamine Treatment Response in Advanced Melanoma

New Insights into the Identification of Metabolites and Cytokines Predictive of Outcome for Patients with Severe SARS-CoV-2 Infection Showed Similarity with Cancer

Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors

Valosin-Containing Protein (VCP)/p97: A Prognostic Biomarker and Therapeutic Target in Cancer

Inhibiting Monocyte Recruitment to Prevent the Pro-Tumoral Activity of Tumor-Associated Macrophages in Chondrosarcoma

Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance

Targeting Autophagy in Breast Cancer

Large extracellular vesicles: Size matters in tumor progression

Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with<i>RAS</i>-mutated metastatic colorectal cancer: the REVOLUTION study protocol

New Prognostic and Predictive Markers in Cancer Progression

Integrated Analysis to Study the Relationship between Tumor-Associated Selenoproteins: Focus on Prostate Cancer

Collaborators (5)

Orlando Paciello

Maria Grazia Vitale

CANNELLA LUCIA

Salvatore Valiante

Alessandra Leone

Make your next move.